Industry | 4 June, 2025 at 1:55 PM
MedLife snaps clinics group in Cluj-Napoca
Romanian private healthcare operator MedLife has announced the full acquisition of Cluj-Napoca-based clinics group Medstar.
Romanian private healthcare operator MedLife has announced the full acquisition of Cluj-Napoca-based clinics group Medstar.
Romanian private healthcare services provider MedLife has recorded a 20% y/y increase in pro-forma consolidated turnover during Q1 2025.
Romanian private healthcare group MedLife has announced an increase in its syndicated credit facility by €50 million, bringing the total to €330 million.
Romanian private healthcare player MedLife is extending its reach by acquiring a majority stake in All Clinic, a healthcare group in the Republic of Moldova.
Romanian private healthcare group Medlife has started on Tuesday a share buyback program that was approved by shareholders in late 2024.
According to the current shareholder structure, MedLife holds the majority stake - 60% - and Mihai Pavel, the group's founder, holds 40%.
In H2 2024, MedLife recorded consolidated pro forma revenue of RON 1.3 billion, up 24% compared to H1 2023, likely to exceed half a €500 million in revenue this year.
The new partnership will accelerate MedLife Group's development in the use of the latest genetic sequencing methodologies and technologies in routine diagnostics.
The study reveals that 83% of Romanians have a plan for their upcoming vacation season. Only 6% do not intend to go on holiday, while 12% have yet to finalize their arrangements.
Travel tech company FlixBus is adding new international coach connections from Romania to Greece and bolstering existing routes to Bulgaria.
EDP, through its subsidiary EDP Renewables, has opened its largest solar park in Romania, located in Albina, taking its total solar and wind capacities in the country to 570 MW.
Dan Air, a private Romanian airline, inaugurated its regular flight service between Bucharest and Damascus on June 15.
Romanian patients wait, on average, 460 days to access innovative medicines, even after these therapies have been approved for reimbursement by the National Agency for Medicines and Medical Devices (ANMDM).